NCT05528120已完成1 期
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
研究概览
简要总结
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate pharmacokinetics of a single oral dose of VC004 capsules under fasting and fed conditions in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
- •Able to complete the study in compliance with the protocol;
- •Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
- •Male and female subjects between the ages of 18 and 45 years, inclusive;
- •At least 50.0kg for male subjects, 45.0kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;
排除标准
- •More than 5 cigarettes per day on average within 3 months prior to screening;
- •History of sensitivity to drugs similar to the study drug;allergic constitution (e.g. allergy to two or more kinds of drugs and food );
- •History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
- •Donation or loss of a significant volume of blood (> 450 mL) within 3 months prior to screening;
- •History of difficulties in swallowing or any history of gastrointestinal, liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion within 6 months prior to screening;
- •Those who Have taken strong inhibitors and / or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2b6, 2c8, 2c19, 3A4 and 3A5) within 28 days before the first administration :strong inhibitors of liver metabolic enzymes such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, oleandomycin etc., strong inducers of liver metabolic enzymes such as rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc; Those who Have taken inhibitors and inducers of P-gp, MRPs, BCRP, OATP and other transporters and transporters within 28 days before the first administration; See Appendix 6 for details;
- •Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;
- •Taking foods that affect CYP3A4 metabolism, such as grapefruit or drinks containing grapefruit within 2 weeks before the first drug administration, or taking high-intensity physical exercises (such as strength training, aerobic training and football playing) within 7 days before the first drug administration, or any other factors that affect drug absorption, distribution, metabolism and excretion;
- •Recent major changes in diet or exercise habits within 7 days before the first medication;
- •Participated in other clinical trials within 3 months before screening (if the subject withdraws from the study before treatment, i.e. has not been randomized or received treatment, he or she can be enrolled in the study);
- •Those who cannot tolerate high-fat meals or have special requirements for diet and cannot accept unified diet；
- •A clinically significant vital signs abnormality during screening (body temperature (axillary temperature) < 36.0 ℃ or > 37.0 ℃; Pulse < 60bpm or > 100bpm; Systolic blood pressure <90mmhg or ≥ 140mmHg, diastolic blood pressure <60mmhg or ≥ 90mmHg);
- •A clinically significant 12-lead ECG abnormality;
- •Positive test results of blood pregnancy or is lactating for female subjects;
- •Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
- •Positive test results for viral hepatitis (including hepatitis B and C), HIV antibody or syphilis antibody during screening;
- •Acute illness or concomitant medication from screening to the first dosing of study medication;
- •Consumption of chocolate or any food or beverages containing caffeine or (rich containing) xanthine within 24 h prior to receiving the first dosing of study medication;
- •Consumption of any product containing alcohol within 24 h prior to receiving the first dosing of study medication, or positive results from a screen for alcohol;
- •Positive results from a screen for urine drug test;
- •Cannot tolerate venipuncture and have a history of needle and blood sickness;
- •Subjects were vaccinated within 4 weeks prior to screening, or planned to be vaccinated during the trial;
- •Any condition which in the opinion of Investigator is not suitable for subjects to participate in the study or who are not suitable to participate according to the epidemic prevention and control requirements of the research center.
研究组 & 干预措施
KG
Experimental
干预措施: VC004 Capsules (Drug)
GK
Experimental
干预措施: VC004 Capsules (Drug)
结局指标
主要结局
Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）
时间窗: Day1-Day8
Peak time(Tmax)
时间窗: Day1-Day8
Maximum Observed Plasma Concentration (Cmax)
时间窗: Day1-Day8
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With RitonavirHCV InfectionNCT00909311Abbott8
已完成
1 期
A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435HealthyNCT01799603Janssen Research & Development, LLC24
已完成
1 期
The Food Effect on Pharmacokinetics of DA-302168SOverweight and ObesityNCT06534346Chendu DIAO Pharmaceutical Group CO., LTD.16
已完成
1 期
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy SubjectsHealthy VolunteerNCT04204629Hanmi Pharmaceutical Company Limited25
已完成
1 期
A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution FormulationHealthyNCT00601432Johnson & Johnson Pharmaceutical Research & Development, L.L.C.24